﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>14</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month>10</Month>
        <DAY>10</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status</ArticleTitle>
    <FirstPage>665</FirstPage>
    <LastPage>674</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.2024.058</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Nadzifa</FirstName>
        <LastName>Nugraheni</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-1918-0155</Identifier>
      </Author>
      <Author>
        <FirstName>Ummi Maryam</FirstName>
        <LastName>Zulfin</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-4133-0669</Identifier>
      </Author>
      <Author>
        <FirstName>Beni</FirstName>
        <LastName>Lestari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5658-0572</Identifier>
      </Author>
      <Author>
        <FirstName>Novia Permata</FirstName>
        <LastName>Hapsari</LastName>
      </Author>
      <Author>
        <FirstName>Muthi</FirstName>
        <LastName>Ikawati</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5968-0130</Identifier>
      </Author>
      <Author>
        <FirstName>Rohmad Yudi</FirstName>
        <LastName>Utomo</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-4803-9417</Identifier>
      </Author>
      <Author>
        <FirstName>Yusuke</FirstName>
        <LastName>Suenaga</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-6902-5386</Identifier>
      </Author>
      <Author>
        <FirstName>Yoshitaka</FirstName>
        <LastName>Hippo</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-4975-1812</Identifier>
      </Author>
      <Author>
        <FirstName>Edy</FirstName>
        <LastName>Meiyanto</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0886-6322</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.2024.058</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>14</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>07</Month>
        <Day>30</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: The HLF and HuH-6 cell lines represent hepatocellular carcinoma (HCC) with different characteristics in chromosome content that may give different drug responses. Here, PGV-1 was intended to challenge the growth-suppressing effect on HLF and HuH-6 and trace the molecular target mechanism of action compared to sorafenib. Methods: We applied MTT cytotoxic assay, colony forming assay, flow cytometry analysis, immunofluorescence assay and western blot assay. Results: PGV-1 exhibited cytotoxic effects on HLF and HuH-6 with IC-50 values of 1 µM and 2 µM, respectively, whereas sorafenib showed less cytotoxicity with IC-50 values of 5 µM and 8 µM respectively. PGV-1 suppressed the cell growth permanently but not for sorafenib. Sorafenib did not change the cell cycle profiles on both cells, but PGV-1 arrested the cells at G2/M with the characteristic of senescent cells and mitotic disarrangement. PGV-1 and sorafenib showed the same effect in downregulating p-EGFR, indicating that both compounds have the same target on EGFR activation or as Tyrosine kinase inhibitors. PGV-1 suppressed the MYCN expression in HuH-6 and HLF cells but stabilized cMYC-T58 indicating that even though the MYCN was downregulated, the cells maintained the active form of cMYC. In this regard, PGV-1 also stabilized the expression of PLK-1 and AurA. Conclusion: PGV-1 elicits stronger cytotoxic properties compared to sorafenib. The lower the MYCN expression, the higher the cytotoxic effect of PGV-1. PGV-1 abrogates cell cycle progression of both cells in mitosis through EGFR inhibition and stabilizes PLK-1 and AurA in correlation with the suppression of MYCN expression.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">PGV-1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HCC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MYCN</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microtubule disarrangement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sorafenib</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>